Compare AJANTA PHARMA with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. REDDYS LAB AJANTA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.4 40.0 63.4% View Chart
P/BV x 7.1 5.5 128.8% View Chart
Dividend Yield % 0.5 0.5 103.1%  

Financials

 AJANTA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DR. REDDYS LAB
Mar-20
AJANTA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,4223,363 42.3%   
Low Rs8982,352 38.2%   
Sales per share (Unadj.) Rs233.51,054.2 22.2%  
Earnings per share (Unadj.) Rs44.0121.9 36.1%  
Cash flow per share (Unadj.) Rs52.2190.2 27.4%  
Dividends per share (Unadj.) Rs9.0025.00 36.0%  
Dividend yield (eoy) %0.80.9 88.7%  
Book value per share (Unadj.) Rs255.1938.7 27.2%  
Shares outstanding (eoy) m88.02166.17 53.0%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.7 183.2%   
Avg P/E ratio x26.423.4 112.6%  
P/CF ratio (eoy) x22.215.0 148.0%  
Price / Book Value ratio x4.53.0 149.4%  
Dividend payout %20.520.5 99.8%   
Avg Mkt Cap Rs m102,081474,831 21.5%   
No. of employees `0006.821.7 31.4%   
Total wages/salary Rs m4,30733,802 12.7%   
Avg. sales/employee Rs Th3,022.68,091.0 37.4%   
Avg. wages/employee Rs Th633.41,561.3 40.6%   
Avg. net profit/employee Rs Th569.1935.8 60.8%   
INCOME DATA
Net Sales Rs m20,554175,170 11.7%  
Other income Rs m2116,206 3.4%   
Total revenues Rs m20,765181,376 11.4%   
Gross profit Rs m5,66424,421 23.2%  
Depreciation Rs m72111,348 6.4%   
Interest Rs m12983 1.2%   
Profit before tax Rs m5,14318,296 28.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273-1,403 -90.7%   
Profit after tax Rs m3,87020,260 19.1%  
Gross profit margin %27.613.9 197.7%  
Effective tax rate %24.8-7.7 -322.8%   
Net profit margin %18.811.6 162.8%  
BALANCE SHEET DATA
Current assets Rs m11,812125,991 9.4%   
Current liabilities Rs m3,77672,141 5.2%   
Net working cap to sales %39.130.7 127.2%  
Current ratio x3.11.7 179.1%  
Inventory Days Days7773 105.9%  
Debtors Days Days82105 77.9%  
Net fixed assets Rs m14,39883,854 17.2%   
Share capital Rs m175831 21.1%   
"Free" reserves Rs m22,277155,157 14.4%   
Net worth Rs m22,452155,988 14.4%   
Long term debt Rs m71,304 0.5%   
Total assets Rs m26,962232,253 11.6%  
Interest coverage x444.319.6 2,265.6%   
Debt to equity ratio x00 3.5%  
Sales to assets ratio x0.80.8 101.1%   
Return on assets %14.49.1 157.4%  
Return on equity %17.213.0 132.7%  
Return on capital %23.012.6 181.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68284,193 12.7%   
Fx outflow Rs m2,10239,616 5.3%   
Net fx Rs m8,58044,577 19.2%   
CASH FLOW
From Operations Rs m3,74829,841 12.6%  
From Investments Rs m-2,228-4,923 45.3%  
From Financial Activity Rs m-1,475-25,159 5.9%  
Net Cashflow Rs m45-266 -17.0%  

Share Holding

Indian Promoters % 73.8 25.5 289.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.4 28.7%  
FIIs % 7.6 35.3 21.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.0 15.3 111.1%  
Shareholders   20,968 75,885 27.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT PHARMOVA   

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 20, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - NATCO PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS